Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence. Issue 5 (8th August 2021) - Frey, Nicolas; Bordogna, Walter; Balas, Bogdana; Ruf, Thorsten; Archer, Venice; Guerini, Elena